Yochai Schonmann1,2,3, Or Goren4,5, Ronen Bareket6,7,8, Doron Comaneshter7, Arnon D Cohen7,9, Shlomo Vinker8. 1. Department of Family Medicine, Rabin Medical Center, Clalit Health Services, Petah Tikva, Israel. yochais@gmail.com. 2. Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel. yochais@gmail.com. 3. Department of Family Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. yochais@gmail.com. 4. Division of Anesthesiology, Pain, and Intensive Care, Tel Aviv Medical Center, Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel. 5. Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel. 6. Department of Family Medicine, Rabin Medical Center, Clalit Health Services, Petah Tikva, Israel. 7. Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel. 8. Department of Family Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 9. Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.
Abstract
PURPOSE: Chronic use of sedative-hypnotics is very common, although not guideline-endorsed. The incidence among new users is not well studied, and there are currently no recommendations favoring any specific agent. We quantified the risk for chronic use in first-time hypnotic users, and the association of the initial choice of hypnotic with later usage patterns. METHODS: We used the computerized database of Israel's largest healthcare provider. All 236,597 new users of sedative-hypnotics between the years 2000-2005 were followed for 10 years. Filled prescriptions in the second, fifth, and tenth years were recorded. The association of the first hypnotic choice (benzodiazepine/Z-drug) with chronic consumption was assessed using multivariate logistic regression. RESULTS: Average age on first use was 63.7 (SD ± 16.4) years. 58.6% were women. Benzodiazepines were initiated in 154,929 (65.5%) of the cases. Benzodiazepine users were older and of lower socioeconomic status, compared to Z-drug users (p < 0.001). On the tenth year, 103,912 (66.8%) of new users claimed ≤ 30 DDDs of hypnotics, 3,1724 (20.4%) were long-term users (≥ 180 DDD/year), and 828 (0.5%) used excessively (≥ 720 DDD/year). Z-drugs were associated with an increased risk of long-term use on the second year [17.3% vs. 12.4%, RR = 1.40 (1.37-1.43)] as well as on the fifth [21.9% vs. 13.9%, RR = 1.58 (1.55-1.61)] and tenth year [25.1% vs. 17.7%, RR = 1.42 (1.39-1.45)], p < 0.0001. Similar results were also observed for daily and excessive use (p < 0.001). CONCLUSIONS: One in five new users of sedative-hypnotics will become a long-term user, but only 0.5% will become excessive users. Z-drugs were associated with an increased risk of chronic use.
PURPOSE: Chronic use of sedative-hypnotics is very common, although not guideline-endorsed. The incidence among new users is not well studied, and there are currently no recommendations favoring any specific agent. We quantified the risk for chronic use in first-time hypnotic users, and the association of the initial choice of hypnotic with later usage patterns. METHODS: We used the computerized database of Israel's largest healthcare provider. All 236,597 new users of sedative-hypnotics between the years 2000-2005 were followed for 10 years. Filled prescriptions in the second, fifth, and tenth years were recorded. The association of the first hypnotic choice (benzodiazepine/Z-drug) with chronic consumption was assessed using multivariate logistic regression. RESULTS: Average age on first use was 63.7 (SD ± 16.4) years. 58.6% were women. Benzodiazepines were initiated in 154,929 (65.5%) of the cases. Benzodiazepine users were older and of lower socioeconomic status, compared to Z-drug users (p < 0.001). On the tenth year, 103,912 (66.8%) of new users claimed ≤ 30 DDDs of hypnotics, 3,1724 (20.4%) were long-term users (≥ 180 DDD/year), and 828 (0.5%) used excessively (≥ 720 DDD/year). Z-drugs were associated with an increased risk of long-term use on the second year [17.3% vs. 12.4%, RR = 1.40 (1.37-1.43)] as well as on the fifth [21.9% vs. 13.9%, RR = 1.58 (1.55-1.61)] and tenth year [25.1% vs. 17.7%, RR = 1.42 (1.39-1.45)], p < 0.0001. Similar results were also observed for daily and excessive use (p < 0.001). CONCLUSIONS: One in five new users of sedative-hypnotics will become a long-term user, but only 0.5% will become excessive users. Z-drugs were associated with an increased risk of chronic use.
Entities:
Keywords:
(MESH); Adult; Benzodiazepines; Drug dependence; Drug tolerance; Hypnotics and sedatives; Insomnia; Risk; Sleep initiation and maintenance disorders; Zolpidem; Zopiclone
Authors: Dieter Riemann; Chiara Baglioni; Claudio Bassetti; Bjørn Bjorvatn; Leja Dolenc Groselj; Jason G Ellis; Colin A Espie; Diego Garcia-Borreguero; Michaela Gjerstad; Marta Gonçalves; Elisabeth Hertenstein; Markus Jansson-Fröjmark; Poul J Jennum; Damien Leger; Christoph Nissen; Liborio Parrino; Tiina Paunio; Dirk Pevernagie; Johan Verbraecken; Hans-Günter Weeß; Adam Wichniak; Irina Zavalko; Erna S Arnardottir; Oana-Claudia Deleanu; Barbara Strazisar; Marielle Zoetmulder; Kai Spiegelhalder Journal: J Sleep Res Date: 2017-09-05 Impact factor: 3.981
Authors: S M Zandstra; J W Furer; E H van de Lisdonk; Hof M van't; J H J Bor; C van Weel; F G Zitman Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2002-03 Impact factor: 4.328
Authors: Inge A T Willems; Wim J M J Gorgels; Richard C Oude Voshaar; Jan Mulder; Peter L B J Lucassen Journal: Fam Pract Date: 2013-03-20 Impact factor: 2.267
Authors: Edouard-Jules Laforgue; Morgane Rousselet; Antoine Claudon; Aurélie Aquizerate; Pascale Jolliet; Marion Istvan; Caroline Victorri-Vigneau Journal: Int J Environ Res Public Health Date: 2022-07-22 Impact factor: 4.614